why choose us

First received: September 01, 2022

Clinical Trial: Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Study Status: Completed

Recruit Status: RECRUITING

Condition: Mantle Cell Lymphoma

Study Type: INTERVENTIONAL


Official Title: Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Brief Summary: To learn if the combination of pirtobrutinib (also called LOXO-305) and venetoclax can help to control mantle cell lymphoma (MCL) that is relapsed (has come back) or refractory (has not responded to therapy).

Read more